EUCTR2010-023237-37-DE进行中（未招募）不适用
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with HER2-positive metastatic breast cancer - E-VITA
GBG Forschungs GmbH (German Breast Group)0 个研究点目标入组 80 人开始时间: 2011年10月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements.
- •2.Complete baseline documentation must be submitted via the web-based data collection system MedCODES® to the GBG Forschungs GmbH.
- •3.Histological confirmed carcinoma of the breast with over-expression of HER2 (IHC3+ or FISH pos., according to current guidelines of AGO). Every effort should be made to make paraffin embedded tissue or slides from the original tumor and/or from metastatic tissue available for confirmation of diagnosis and additional translational research.
- •4.Locally advanced or metastatic stage of disease not suitable for surgery or radiotherapy alone.
- •5.Patients must have either measurable or non-measurable target lesions according to RECIST criteria. Complete staging work-up within 4 weeks prior to registration. All patients must have chest X-ray (PA and lateral), abdominal ultrasound or CT scan or MRI, and bone scan. In case of positive bone scan, bone X-ray is mandatory. Other tests may be performed as clinically indicated.
- •6.The following previous systemic treatments are eligible:
- •Previous treatment with trastuzumab either as (neo)adjuvant treatment for early breast cancer
- •and/or first and/or second line treatment for metastatic breast cancer,
- •adjuvant and up to 2 chemotherapy regimen for metastatic breast cancer,
- •if previous chemotherapy regimen were anthracycline based, the maximum cumulative dose of prior anthracycline therapy must not exceed 360 mg/m² for doxorubicin and 720 mg/m² for epirubicin,
- •adjuvant endocrine therapy,
- •palliative endocrine treatments,
- •treatment with bisphosphonates (adjuvant and/or palliative),
- •at least 4 weeks since radiotherapy, with full recovery. The measurable disease must be completely outside the radiation field or there must be pathologic proof of progressive disease.
- •7.Age >18 years.
- •8.ECOG performance status 0-2.
- •9.Laboratory requirements:
- •Absolute neutrophil count ?1500 cells/?l,
- •hemoglobin = 10.0 g/dL (hemoglobin <10.0 g/dL is acceptable if it is corrected by growth factor or transfusion),
- •platelet count ?100,000 cells/?l,
- •bilirubin ? 1.5x the upper limit of normal for the institution (ULN),
- •elevation of transaminases and alkaline phosphatase < 2.5x ULN or <5x ULN for patients with liver metastases,
- •creatinine ? 1.5 x ULN or creatinine-clearance > 40 ml/min (according to Cockroft Gault),
- •negative pregnancy test (urine or serum) within 14 days prior to registration for all women of childbearing potential.
- •10.Normal cardiac ejection function as determined by cardiac ultrasound (LVEF above institutional normal range).
- •11.A female either of:
- •- Non-childbearing potential i.e., physiologically incapable of becoming pregnant because of history of hysterectomy, bilateral oophorectomy (ovarectomy), bilateral tubal ligation or postmenopausal status.
- •- Childbearing potential with a negative serum pregnancy test within 2 weeks prior to registration, preferably as close to the first dose as possible, and agrees to use adequate contraception. Acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follow:
- •An intrauterine device with a documented failure rate of less than 1% per year.
排除标准
- •1.Known hypersensitivity reaction to the compounds or incorporated substances (e.g. halichondrin B and/or halichondrin B chemical derivative).
- •2.Patients who have received eribulin or lapatinib before.
- •3.Concurrent immunotherapy or hormonal therapy (anti-hormonal, contraceptive and/or replacement therapy). Bisphosphonates may be continued.
- •4.Life expectancy of less than 3 months.
- •5.Parenchymal brain metastases, unless adequately treated by neurosurgery, radiotherapy, radiosurgery or a combination.
- •6.Any ongoing toxicity from prior anti-cancer therapy that is
- •grade >1 and/or that is progressing in severity, except alopecia or for stable sensory neuropathy Grade 2.
- •7.Known or suspected congestive heart failure (>NYHA I) and/or coronary heart disease, angina pectoris requiring anti-anginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, un- or poorly controlled arterial hypertension (i.e. BP >150/100 mmHg under treatment with two antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease.
- •8.Currently active infection.
- •9.History of other malignancies within the last 5 years which could affect the diagnosis, assessment or prognosis of metastatic breast cancer.
- •10.Malabsorption syndrome or insufficient gastrointestinal function, preexisting diagnosis of ulcerative colitis.
- •11.Concurrent treatment with other experimental drugs; participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.
- •12.Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject’s safety, provision of informed consent, or compliance to study procedures.
研究者
相似试验
进行中（未招募）
1 期
A randomized study to explore the efficacy and feasibility of rotations between sunitinib and everolimus versus sequential treatment of sunitinib and everolimus until progression in patients with renal cancer.EUCTR2012-001337-13-ESAPRO115
进行中（未招募）
1 期
A randomized study to explore the efficacy and feasibility of rotations between sunitinib and everolimus versus sequential treatment of sunitinib and everolimus until progression in patients with renal cancer.Metastatic clear cell renal cancerMedDRA version: 14.1Level: LLTClassification code 10038416Term: Renal clear cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001337-13-GRAPRO115
已完成
2 期
A randomized phase II study to explore the efficacy and feasibility of upfront bi-monthly rotations between Everolimus and Pazopanib with sequential treatment of first line Pazopanib and second line Everolimus until progression in patients with advanced or metastatic clear cell renal cancer.10038364Kidney cancerRenal cancerNL-OMON39600Werkgroep Immunotherapie Nederland voor Oncologie100
进行中（未招募）
1 期
A study to investigate if alternating Pazopanib and Everolimus avoids or postpones resistanceEUCTR2011-000127-32-NLWerkgroep Immunotherapie Nederland voor Oncologie100
进行中（未招募）
不适用
Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormone receptor-positive metastatic breast cancerMetastatic breast cancerEUCTR2005-005581-36-ATSchering AG72